Underweight CL: trim 20-25% into $91-93 strength, hold core at $87-89 structural support with $90 covered call overlay
Bear case wins on PEG/valuation (street embeds 62% EPS recovery from $2.54 to $4.11 which is heroic against 3.2% 5-year revenue CAGR), technical deterioration (MACD negative, below 10-EMA at $91.48 and 50-SMA at $91.69, forming fast-MA death cross), and genuine Q3 input cost test (Q2's 140bps GM expansion reflected pre-shock hedging, not durable margin power). Bear loses on 8/21 lesson (Underweight call returned +1.6% raw/+1.9% alpha near structural support), rising 200-SMA ($86.41, steepening not flattening), and yield floor (2.3% yield pays ~$0.53/share quarterly to wait). Underweight is correct vs Hold (8/24 and 8/26 prior Holds leaked -1.6% and -1.9% alpha without active trim or hedge) and vs Sell (structural bid historically reasserts before technicals resolve into breakdowns). High-quality franchise, wrong price ($90.96), deteriorating tape, real forward cost test in Q3 — trim and wait.
| Position | Action |
|---|---|
| Price rallies to $91-93 retest zone | Trim 20-25% of position (vs trader's excessive 50%) |
| Price declines to $87-89 re-engagement zone with 200-SMA convergence | Re-enter trimmed portion; asymmetric R/R setup |
| Retained core position (~75% of trimmed position) | Install $90 covered call overlay for ~0.5% cost basis reduction via premium capture |
| Close below $89.56 with volume >5M | Hard stop on remaining core position |
CL is a defensive powerhouse with strengthening fundamentals: accelerating revenue growth, margin expansion under cost pressure, and volume-led demand that differentiates it from slower-growing peers, all supporting a BUY rating.
| Indicator | Value | Signal |
|---|---|---|
| 10-EMA | 91.48 | bearish |
| 50-SMA | 91.69 | bearish |
| 200-SMA | 86.56 | bullish |
| Bollinger Upper | 94.05 | neutral |
| Bollinger Middle (20-SMA) | 91.81 | neutral |
| Bollinger Lower | 89.56 | neutral |
| MACD Line | -0.08 | bearish |
| MACD Signal | 0.01 | bearish |
| MACD Histogram | -0.09 | bearish |
| RSI (14) | 47.66 | neutral |
| ATR (14) | 1.93 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price approaches $87-89 with 200-SMA convergence
Then: Add back trimmed shares for asymmetric risk/reward
CL has a durable competitive moat through brand equity, pricing power, and global distribution
↩ rebuts: “Bear's 'commoditized soap company' and 'private label pressure' claims”
· concedes: North America is the weakest geography (bear is correct on this point); US consumer softness is a legitimate concern worth monitoring; TTM P/E is technically 35.8x (though inflated by one-time impairment); Growth rate currently assumed at 3% by bear; bull argues it's inflecting higher
CL is a yield trap wrapped in a premium multiple — priced at 22x forward earnings for a 3.2% five-year CAGR, with deteriorating technicals, a balance sheet hollowed by buybacks, and a 2.3% dividend yield below risk-free rates.
· concedes: CL has genuine pricing power — margin trajectory proves it; Beta of 0.327 makes CL genuinely defensive ballast; 63-year dividend streak is real and meaningful; Net debt/EBITDA at 1.3x is comfortable; Long-term uptrend off October 2025 low is intact
→ vs conservative: Beta of 0.327 measures volatility, not direction; low beta stocks still decline when fundamentals break
→ vs conservative: The 'defensive ballast' argument only works at reasonable valuations; paying 22x forward earnings for 3.2% growth is expensive insurance
→ vs conservative: The 'pullback inside an intact long-term trend' characterization ignores the momentum regime change in progress
→ vs neutral: Q2 earnings beat and raised guidance ignored that gross margin expansion was on pre-shock hedged input costs; Q3 will show real margin compression
→ vs neutral: Defensives benefit from rate cuts, not 'higher for longer'; elevated rates compress their multiples
→ vs neutral: The bullish catalyst window is narrow and requires multiple things to go right; the bearish case requires only one (close below 89.56)
→ vs conservative: The 200-SMA at 86.56 is not a magical floor; five percent is a major move for this name with 2.3 ATRs distance to that level
→ vs conservative: Holding a fully-valued defensive name into margin compression, rising rates, and weakening consumer is not safe—it is expensive
| neutral |
| VWMA | 91.61 (8/27), 91.74 (8/26), 91.66 (7/31), 90.60 (7/02) | neutral |
Support: 89.47 · 89.56 · 86.56 | Resistance: 92.55 · 93.49 · 94.05
CL shows a mixed technical picture with short-term weakness (price below fast MAs, MACD negative) offset by intact long-term uptrend (well above 200-SMA) and neutral RSI. The stock is in a compression regime with Bollinger Bands narrowed to a 4.5% width around the 91.81 midline, suggesting an imminent directional move. Volume on the 8/27 decline was the lightest of the 30-day window at 3.2M shares, indicating digestion rather than distribution. VWMA stability near 91.6-91.7 confirms institutional absence of selling pressure. The 89.50-94.00 range is likely to hold absent a catalyst, with 91.50-91.70 (10-EMA/50-SMA cluster) as the pivotal pivot zone. A HOLD rating reflects a defensive staple in pullback within an intact long-term base, with add/reduce triggers at 92.55 and 89.56 respectively.
Market Cap
$72.51 billion
P/E (TTM)
35.81x
Forward P/E
22.14x
PEG Ratio
1.76
Dividend Yield
2.30%
Beta
0.327
Revenue (TTM)
$21.05B
Gross Margin
60.4%
Operating Margin
21.0%
Net Margin
9.7%
ROA
15.8%
Free Cash Flow (TTM)
$3.46B
Operating CF (2025)
$4.20B
CapEx (2025)
$0.56B
Total Debt
$7.86B
Net Debt
$6.49B
Net Debt / EBITDA
~1.3x
Current Ratio
1.03
Revenue YoY (Q2 2026)
+4.9%
Revenue 5Y CAGR
~3.2%
52-Week High
$99.33
52-Week Low
$74.55
50-Day MA
$91.90
200-Day MA
$87.32
Revenue 2025
$20.38B
Diluted EPS 2025
$2.63
Normalized Net Income 2025
$2.82B
Dividends Paid 2025
$1.82B
Buybacks 2025
$1.21B
Strengths
Concerns
Colgate-Palmolive (CL) is a high-quality defensive consumer staples company trading near 52-week highs at ~22x forward P/E. The company generates strong free cash flow ($3.46B TTM), maintains 60%+ gross margins demonstrating pricing power, and offers a 2.3% dividend yield with a track record of decades of consecutive growth. While the defensive characteristics (beta 0.327) and emerging market exposure (~40% of revenue) are attractive, the current valuation leaves limited margin of safety for new entrants, warranting a HOLD rating.
Macro: Hawkish monetary backdrop with 88% probability of no Fed cuts in 2026 keeps discount rates elevated and pressures CL's premium valuation multiple. Iran/Hormuz oil disruption (~3 mb/d draws Feb–Aug 2026) creates commodity-cost headwinds. Soft landing remains base case with 8% US recession probability. Consumer stress emerging (Walmart -10% MoM) signals cracks in spending even for essentials, while competitive intensity rises from Amazon/Walmart 'doubling down' on shopper share.